Clinical and genetic characteristics of the Russian cohort of children with nephropathic cystinosis: single center experience

Introduction. Nephropathic cystinosis (NC) is an extremely rare hereditary disease characterized by the intralysosomal accumulation of cystine crystals caused by mutations in the CTNS gene. NC is the most common cause of Fanconi syndrome in children, which has a poor prognosis without continued pathogenetic therapy, mainly affecting renal function.

The aim of the work is to determine the features of the clinical course of NC, the experience of diagnosis and treatment in a multidisciplinary hospital of the federal center.

Materials and methods. The retrospective study included 37 NC patients (19 girls, 18 boys) for the period from 2008 to 2024.

Results. Manifestations of Fanconi syndrome were noted in all patients; the age of verification of symptoms ranged from 2 to 119 months, the median was 7 [6; 14] months. At the time of diagnosis at the age 8 to 294 months, median 27 [19; 71] months, in 17 (46%) children documented a decrease in eGFR < 60 ml/min/1.73 m². An extended deletion of 57 thousand pairs of nucleotides was detected in 17 (46%) patients. Renal replacement therapy was initiated in 24 (65%) patients, median age 8.7 [7.7; 11.9] years. Kidney transplantation was performed in 21 patients, median age was 10.2 years (8.8; 13.0), there were no cases of loss of allograft. Pathogenetic cysteamine therapy was initiated in 36 (97.3%) children, range 8 to 174 months, median 33 [23; 82] months, was achieved a decrease the concentration of cystine leukocytes and a decrease in the frequency of extrarenal complications. There were a significant slowdown in the rate of decrease in renal function to CKD stage 3 and stage 5 with early initiation of cysteamine bitatrate and subsequent adherence to therapy.

Conclusion. Nephropathic cystinosis is an important problem in Pediatrics due to the extremely late diagnosis and lack of alertness of primary care specialists. Early initiation of supportive and pathogenetic therapy allows improving the condition and development of patients, as well as slowdown the rate of decrease in renal function and extrarenal damage.

Contribution:
Maltseva V.V., Savostyanov K.V., Tsygin A.N. — concept and design of the study;
Maltseva V.V., Ananin P.V., Vashurina T.V., Zrobok O.I., Mazanova N.N., Milovanova A.M., Nikolaeva R.A., Tsygina E.N., Petrachkova M.S. — data collection and processing;
Maltseva V.V. — writing the text and statistical processing of the data;
Pushkov A.A., Tsygin A.N. — editing the text.
All co-authors — approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: December 27, 2024
Accepted: January 30, 2025
Published: February 28, 2025

1. Gahl W.A., Thoene J.G., Schneider J.A. Cystinosis. N. Engl. J. Med. 2002; 347(2): 111–21. https://doi.org/10.1056/NEJMra020552

2. Elmonem M.A., Veys K.R., Soliman N.A., van Dyck M., van den Heuvel L.P., Levtchenko E. Cystinosis: a review. Orphanet J. Rare Dis. 2016; 11: 47. https://doi.org/10.1186/s13023-016-0426-y

3. Langman C.B., Barshop B.A., Deschênes G., Emma F., Goodyer P., Lipkin G., et al. Controversies and research agenda in nephropathic cystinosis: conclusions from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int. 2016; 89(6): 1192–203. https://doi.org/10.1016/j.kint.2016.01.033

4. Bäumner S., Weber L.T. Nephropathic cystinosis: symptoms, treatment, and perspectives of a systemic disease. Front. Pediatr. 2018; 6: 58. https://doi.org/10.3389/fped.2018.00058

5. Kagan M.Yu., Levtchenko E.N., Tsygin A.N. Diagnosis of infantile cystinosis: a sentence or a guide for action? Review and a case report. Nefrologiya i dializ. 2008; 10(3-4): 265–72. https://elibrary.ru/kaybkj (in Russian)

6. Tsygin A.N., Kagan M.Yu., Kartamysheva N.N., Karagulyan N.A., Levchenko E.N. Nephropathic cystinosis. An underestimated problem of pediatric nephrology. Klinicheskaya nefrologiya. 2011; (4): 20–3. https://elibrary.ru/ogiuix (in Russian)

7. Schwartz G.J., Muñoz A., Schneider M.F., Mak R.H., Kaskel F., Warady B.A., et al. New equations to estimate GFR in children with CKD. J. Am. Soc. Nephrol. 2009; 20(3): 629–37. https://doi.org/10.1681/asn.2008030287

8. Savostyanov K.V., Mazanova N.N., Pushkov A.A., Ananyin P.V., Sukhozhenko A.V., Smirnov P.V., et al. Chromatography-mass spectrometry and molecular genetic diagnosis of cystinosis in Russian children. Pediatriya. 2018; 97(5): 71–8. https://doi.org/10.24110/0031-403X-2018-97-5-71-78 https://elibrary.ru/xzirtf (in Russian)

9. Savostyanov K.V., Pushkov A.A., Shchagina O.A., Maltseva V.V., Suleymanov E.A., Zhanin I.S., et al. Genetic landscape of nephropathic cystinosis in Russian children. Front. Genet. 2022; 13: 863157. https://doi.org/10.3389/fgene.2022.863157

10. Nesterova G., Williams C., Bernardini I., Gahl W.A. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy. Pediatr. Nephrol. 2015; 30(6): 945–51. https://doi.org/10.1007/s00467-014-3018-x

11. Emma F., Hoff W.V., Hohenfellner K., Topaloglu R., Greco M., Ariceta G., at al. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int. 2021; 100(5): 1112–3. https://doi.org/10.1016/j.kint.2021.06.019

12. Van Stralen K.J., Emma F., Jager K.J., Verrina E., Schaefer F., Laube G.F. Improvement in the renal prognosis in nephropathic cystinosis. Clin. J. Am. Soc. Nephrol. 2011; 6(10): 2485–91. https://doi.org/10.2215/CJN.02000311

13. Greco M., Brugnara M., Zaffanello M., Taranta A., Pastore A., Emma F. Long-term outcome of nephropathic cystinosis: a 20-year single-center experience. Pediatr. Nephrol. 2010; 25(12): 2459–67. https://doi.org/10.1007/s00467-010-1641-8

14. Bertholet-Thomas A., Berthiller J., Tasic V., Kassai B., Otukesh H., Greco M., et al. Worldwide view of nephropathic cystinosis: results from a survey from 30 countries. BMC Nephrol. 2017; 18(1): 210. https://doi.org/10.1186/s12882-017-0633-3

15. Nießl C., Boulesteix A.L., Oh J., Palm K., Schlingmann P., Wygoda S., et al. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis. Mol. Genet. Metab. 2022; 136(4): 268–73. https://doi.org/10.1016/j.ymgme.2022.06.010

16. Ariceta G., Giordano V., Santos F. Effects of long-term cysteamine treatment in patients with cystinosis. Pediatr. Nephrol. 2019; 34(4): 571–8. https://doi.org/10.1007/s00467-017-3856-4

17. Kizilbash S.J., Snyder J., Vock D.M., Chavers B.M. Trends in kidney transplant outcomes in children and young adults with cystinosis. Pediatr. Transplant. 2019; 23(8): e13572. https://doi.org/10.1111/petr.13572

18. Hohenfellner K., Rauch F., Ariceta G., Awan A., Bacchetta J., Bergmann C., et al. Management of bone disease in cystinosis: Statement from an international conference. J. Inherit. Metab. Dis. 2019; 42(5): 1019–29. https://doi.org/10.1002/jimd.12134